List of Protonix drug patents
Protonix is owned by Wyeth Pharms.
Protonix contains Pantoprazole Sodium.
Protonix has a total of 8 drug patents out of which 0 drug patents have expired.
Protonix was authorised for market use on 14 November, 2007.
Protonix is available in for suspension, delayed release;oral dosage forms.
Protonix can be used as erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd.
The generics of Protonix are possible to be released after 07 December, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 3 months from now) | |
| US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 3 months from now) | |
| US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 3 months from now) | |
|
US7838027 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(1 year, 9 months from now) | |
|
US7550153 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(1 year, 9 months from now) | |
|
US7553498 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(1 year, 9 months from now) | |
| US7544370 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Jun, 2026
(3 years from now) | |
|
US7544370 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Dec, 2026
(3 years from now) | |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 14 November, 2007
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL
PROTONIX family patents
6
United States
1
Colombia
1
Ecuador
1
Australia
1
Israel
1
Korea, Republic of
1
Canada
1
Yugoslavia
1
New Zealand
1
Spain
1
Peru
1
Malaysia
1
Costa Rica
1
Singapore
1
Ukraine
1
Russia
1
Poland
1
Japan
1
Norway
1
Hong Kong
1
Guatemala
1
Mexico
1
Argentina
1
Brazil
1
RS
1
South Africa
1
China
1
Taiwan
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic